Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Levels of the autophagy-related 5 protein affect progression and metastasis of pancreatic tumors in mice.
Gastroenterology 156, 203-217.e20 (2019)
BACKGROUND AND AIMS: Cells in pancreatic ductal adenocarcinoma (PDAC) undergo autophagy, but its effects vary with tumor stage and genetic factors. We investigated the consequences of varying levels of the autophagy related 5 (Atg5) protein on pancreatic tumor formation and progression. METHODS: We generated mice that express oncogenic Kras in primary pancreatic cancer cells and have homozygous disruption of Atg5 (A5; Kras) or heterozygous disruption of Atg5 (A5(+/-); Kras), and compared them with mice with only oncogenic Kras (controls). Pancreata were analyzed by histology and immunohistochemistry. Primary tumor cells were isolated and used to perform transcriptome, metabolome, intracellular calcium, extracellular cathepsin activity, and cell migration and invasion analyses. The cells were injected into wild-type littermates, and orthotopic tumor growth and metastasis were monitored. Atg5 was knocked down in pancreatic cancer cell lines using small hairpin RNAs; cell migration and invasion were measured, and cells were injected into wild-type littermates. PDAC samples were obtained from independent cohorts of patients and protein levels were measured on immunoblot and immunohistochemistry; we tested the correlation of protein levels with metastasis and patient survival times. RESULTS: A5(+/-); Kras mice, with reduced Atg5 levels, developed more tumors and metastases, than control mice, whereas A5; Kras mice did not develop any tumors. Cultured A5(+/-); Kras primary tumor cells were resistant to induction and inhibition of autophagy, had altered mitochondrial morphology, compromised mitochondrial function, changes in intracellular Ca2thorn oscillations, and increased activity of extracellular cathepsin L and D. The tumors that formed in A5(+/-); Kras mice contained greater numbers of type 2 macrophages than control mice, and primary A5(+/-); Kras tumor cells had up-regulated expression of cytokines that regulate macrophage chemoattraction and differentiation into M2 macrophage. Knockdown of Atg5 in pancreatic cancer cell lines increased their migratory and invasive capabilities, and formation of metastases following injection into mice. In human PDAC samples, lower levels of ATG5 associated with tumor metastasis and shorter survival time. CONCLUSIONS: In mice that express oncogenic Kras in pancreatic cells, heterozygous disruption of Atg5 and reduced protein levels promotes tumor development, whereas homozygous disruption of Atg5 blocks tumorigenesis. Therapeutic strategies to alter autophagy in PDAC should consider the effects of ATG5 levels to avoid the expansion of resistant and highly aggressive cells.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
19.233
3.884
22
23
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Atg5 Levels ; Pancreatic Carcinogenesis ; Ca2+ ; Mitochondria ; Cathepsins; Cancer; Cells; Mitochondria; Mechanisms; Resistance; Dynamics; Lysosome; Basal
Sprache
englisch
Veröffentlichungsjahr
2019
Prepublished im Jahr
2018
HGF-Berichtsjahr
2018
ISSN (print) / ISBN
0016-5085
e-ISSN
1528-0012
Zeitschrift
Gastroenterology
Quellenangaben
Band: 156,
Heft: 1,
Seiten: 203-217.e20
Verlag
Elsevier
Verlagsort
1600 John F Kennedy Boulevard, Ste 1800, Philadelphia, Pa 19103-2899 Usa
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Experimental Genetics (IEG)
Research Unit Analytical Pathology (AAP)
Institute of Diabetes and Obesity (IDO)
Institute of Diabetes and Cancer (IDC)
Research Unit Analytical Pathology (AAP)
Institute of Diabetes and Obesity (IDO)
Institute of Diabetes and Cancer (IDC)
POF Topic(s)
30201 - Metabolic Health
30205 - Bioengineering and Digital Health
90000 - German Center for Diabetes Research
30205 - Bioengineering and Digital Health
90000 - German Center for Diabetes Research
Forschungsfeld(er)
Genetics and Epidemiology
Enabling and Novel Technologies
Helmholtz Diabetes Center
Enabling and Novel Technologies
Helmholtz Diabetes Center
PSP-Element(e)
G-500600-001
G-500390-001
G-501900-221
G-501900-253
G-500390-001
G-501900-221
G-501900-253
WOS ID
WOS:000453401000034
Scopus ID
85058479942
PubMed ID
30296435
Erfassungsdatum
2018-10-22